The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Somatic TP53 Mutations in the Era of Genome Sequencing
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The most frequently mutated region of p53 in human cancers is the DBD, with 90% of the oncogenic mutations lying in this domain (see Hainaut and Pfeifer 2016).”
From Structural Evolution and Dynamics of the p53 Proteins (2017) · cites this paper as Hainaut and Pfeifer 2016
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
METABRIC Group, Curtis, C., Shah, S. P., Chin, S.-F., Turashvili, G., Rueda, O. M., Dunning, M. J., Speed, D., Lynch, A. G., Samarajiwa, S., et al. (2012) · Nature · doi:10.1038/nature10983 · Cited by 6,097
A landscape of driver mutations in melanoma
Hodis, E., Watson, I. R., Kryukov, G. V., Arold, S. T., Imielinski, M., Theurillat, J.-P., Nickerson, E., Auclair, D., Li, L., Place, C., et al. (2012) · Cell · doi:10.1016/j.cell.2012.06.024 · Cited by 2,610
TP53 mutations in human cancers: origins, consequences, and clinical use.
Olivier, M., Hollstein, M., & Hainaut, P. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001008 · Cited by 2,199 · cited 4×
“However, despite numerous studies reporting an association between somatic TP53 mutations and poor prognosis and unfavorable treatment outcomes (Olivier et al. 2010; Robles and Harris 2010), the only accepted recommendation for clinical testing to date is for chronic lymphocytic leukemia (CLL), in which somatic TP53 m…”
BackgroundMethodInfluentialSelf-citationA comprehensive catalogue of somatic mutations from a human cancer genome
Pleasance, E. D., Cheetham, R. K., Stephens, P. J., McBride, D. J., Humphray, S. J., Greenman, C. D., Varela, I., Lin, M.-L., Ordóñez, G. R., Bignell, G. R., et al. (2010) · Nature · doi:10.1038/nature08658 · Cited by 1,696
Preferential Formation of Benzo[ a ]pyrene Adducts at Lung Cancer Mutational Hotspots in P53
Denissenko, M. F., Pao, A., Tang, M.-S., & Pfeifer, G. P. (1996) · Science · doi:10.1126/science.274.5286.430 · Cited by 1,650
Self-citationThe genetic basis of early T-cell precursor acute lymphoblastic leukaemia
Zhang, J., Ding, L., Holmfeldt, L., Wu, G., Heatley, S. L., Payne-Turner, D., Easton, J., Chen, X., Wang, J., Rusch, M., et al. (2012) · Nature · doi:10.1038/nature10725 · Cited by 1,596 · cited 2×
“In hematopoietic malignancies, TP53 mutations are less frequent (10%–15%) but are among the 10 most frequent SMGs in five of six documented malignancies (the exception is pediatric acute lymphoblastic leukemia [Zhang et al. 2012]).”
BackgroundMutant p53 in Cancer: New Functions and Therapeutic Opportunities
Muller, P. A. J., & Vousden, K. H. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.01.021 · Cited by 1,545
The IARC TP53 database: new online mutation analysis and recommendations to users
Olivier, M., Eeles, R., Hollstein, M., Khan, M. A., Harris, C. C., & Hainaut, P. (2002) · Human Mutation · doi:10.1002/humu.10081 · Cited by 1,248
When mutants gain new powers: News from the mutant p53 field
Brosh, R., & Rotter, V. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2693 · Cited by 1,132
Research works printed but not linked: 76
- 10.1016/j.celrep.2012.12.008 · DOI · Paper page
- 10.1126/science.2649981 · DOI · Paper page
- 10.1002/ijc.2910460515 · DOI · Paper page
- 10.1093/nar/26.1.200 · DOI
- 10.1016/S1470-2045(11)70094-8 · DOI
- 10.1073/pnas.88.22.10124 · DOI · Paper page
- 10.1038/350429a0 · DOI · Paper page
- 10.1126/scitranslmed.3006802 · DOI · Paper page
- 10.1093/carcin/bgu134 · DOI · Paper page
- 2014, Mutation of TP53 and alteration of p14arf expression in EGFR- and KRAS-mutated lung adenocarcinomas, Clin Lung Cancer, 15, 124, 10.1016/j.cllc.2013.08.003 · DOI
- 10.1038/sj.onc.1206929 · DOI
- 10.1038/sj.onc.1202214 · DOI
- 2014, microRNAs: Short non-coding bullets of gain of function mutant p53 proteins, Oncoscience, 1, 427, 10.18632/oncoscience.52 · DOI
- 10.1038/srep07063 · DOI
- 10.1038/ng1093 · DOI · Paper page
- 2011, p53 status influences response to tamoxifen but not to fulvestrant in breast cancer cell lines, Int J Cancer, 128, 1813, 10.1002/ijc.25512 · DOI
- 10.1007/s10549-010-0819-x · DOI
- 10.1186/bcr3179 · DOI
- 10.1073/pnas.94.20.10895 · DOI · Paper page
- 10.1016/j.canlet.2009.02.057 · DOI
- 10.1093/carcin/bgs135 · DOI
- 1994, Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis, Cancer Res, 54, 4855
- 2000, p53 and human cancer: The first ten thousand mutations, Adv Cancer Res, 77, 81
- 10.1016/j.cell.2011.02.013 · DOI · Paper page
- 10.1016/S0027-5107(99)00162-1 · DOI · Paper page
- 2013, Analysis of TP53 mutation spectra reveals the fingerprint of the potent environmental carcinogen, aristolochic acid, Mutat Res, 753, 41, 10.1016/j.mrrev.2013.02.003 · DOI
- 2013, Validation of a yeast functional assay for p53 mutations using clonal sequencing, J Pathol, 231, 441, 10.1002/path.4243 · doi:10.1002/path.4243
- 10.1002/ijc.25118 · DOI
- 10.1101/cshperspect.a026039 · DOI · Paper page
- 10.1073/pnas.1431692100 · DOI · Paper page
- 10.1101/cshperspect.a000927 · DOI · Paper page
- 10.1038/nrc3721 · DOI · Paper page
- 1993, MDM2 gene amplification in metastatic osteosarcoma, Cancer Res, 53, 16
- 2013, The importance of codon context for understanding the Ig-like somatic hypermutation strand-biased patterns in TP53 mutations in breast cancer, Cancer Genet, 206, 222, 10.1016/j.cancergen.2013.05.016 · DOI
- 10.1038/ng891 · DOI
- 2001, UV-induced DNA damage and mutations in Hupki (human p53 knock-in) mice recapitulate p53 hotspot alterations in sun-exposed human skin, Cancer Res, 61, 8158
- 10.1016/j.molonc.2013.12.015 · DOI
- 10.1016/j.molcel.2009.01.028 · DOI · Paper page
- 10.1038/onc.2010.26 · DOI
- 10.1038/cdd.2011.120 · DOI
- 10.1038/75586 · DOI · Paper page
- 10.1093/nar/gkj518 · DOI · Paper page
- 10.1158/1055-9965.EPI-06-0790 · DOI
- 10.1016/0092-8674(91)90384-B · DOI · Paper page
- 10.1158/0008-5472.CAN-06-4229 · DOI
- 10.1038/342705a0 · DOI · Paper page
- 2014, Association of a germline copy number polymorphism of APOBEC3A and APOBEC3B with burden of putative APOBEC-dependent mutations in breast cancer, Nat Genet, 246, 487
- 10.1158/1078-0432.CCR-05-1029 · DOI · Paper page
- 2013, Association between TP53 R249S mutation and polymorphisms in TP53 intron 1 in hepatocellular carcinoma, Genes Chromosomes Cancer, 52, 912, 10.1002/gcc.22086 · DOI
- 10.1097/CCO.0000000000000152 · DOI
- 10.1002/ijc.11548 · DOI · Paper page
- 10.1038/nature08629 · DOI · Paper page
- 10.1056/NEJMoa073770 · DOI · Paper page
- 10.1126/scitranslmed.3006086 · DOI · Paper page
- 10.1016/j.cell.2011.12.013 · DOI · Paper page
- 10.1006/geno.1996.0639 · doi:10.1006/geno.1996.0639
- 10.18632/oncotarget.3115 · DOI
- 10.1038/nrc3816 · DOI · Paper page
- 10.1101/cshperspect.a001016 · DOI · Paper page
- 10.1183/09031936.00097311 · DOI
- 10.1038/sj.onc.1209405 · DOI
- 10.1158/1078-0432.CCR-13-2943 · DOI · Paper page
- 10.1158/1078-0432.CCR-11-2260 · DOI · Paper page
- 10.1002/path.2988 · DOI
- 10.1002/humu.22562 · DOI
- 10.1038/nature11017 · DOI · Paper page
- 10.1182/blood-2014-01-546150 · DOI · Paper page
- 10.1126/science.2554494 · DOI · Paper page
- 10.1021/bi025540i · DOI
- 1992, Carcinogens leave fingerprints, Nature, 355, 209, 10.1038/355209a0 · DOI · Paper page
- 2015, FHIT loss-induced DNA damage creates optimal APOBEC substrates: Insights into APOBEC-mediated mutagenesis, Oncotarget, 6, 3409, 10.18632/oncotarget.2636 · DOI
- 10.1038/nrg3539 · DOI · Paper page
- 10.1038/nrc2584 · DOI · Paper page
- 10.1111/cas.12302 · DOI
- 10.1073/pnas.152333199 · DOI · Paper page
- 10.1038/nature15251 · DOI · Paper page
Cited by
Targeting p53 pathways: mechanisms, structures, and advances in therapy
Wang, H., Guo, M., Wei, H., & Chen, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01347-1 · Cited by 1,016
Mutational processes shape the landscape of TP53 mutations in human cancer
Giacomelli, A. O., Yang, X., Lintner, R. E., McFarland, J. M., Duby, M., Kim, J., Howard, T. P., Takeda, D. Y., Ly, S. H., Kim, E., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0204-y · Cited by 556
Proteogenomic Characterization of Endometrial Carcinoma
Dou, Y., Kawaler, E. A., Cui Zhou, D., Gritsenko, M. A., Huang, C., Blumenberg, L., Karpova, A., Petyuk, V. A., Savage, S. R., Satpathy, S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.01.026 · Cited by 485
“Effects of TP53 Mutations TP53 is the most commonly mutated gene in human cancers (Hainaut and Pfeifer, 2016).”
BackgroundDNA damage checkpoint kinases in cancer
Smith, H. L., Southgate, H., Tweddle, D. A., & Curtin, N. J. (2020) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2020.3 · Cited by 322
Mechanisms of UV-induced mutations and skin cancer
Pfeifer, G. P. (2020) · Genome Instability & Disease · doi:10.1007/s42764-020-00009-8 · Cited by 237
Self-citation
Metadata
- Authors
- Hainaut, P., & Pfeifer, G. P.
- Venue
- Cold Spring Harbor Perspectives in Medicine
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2016-08-08
- Volume
- 6
- Issue
- 11
- Pages
- a026179
- ISSN
- 2157-1422
- Cited by
- 231
- References
- 17
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Somatic TP53 Mutations in the Era of Genome Sequencing. https://app.cochat.ai/papers/10.1101/cshperspect.a026179
- The paper
- Hainaut, P., & Pfeifer, G. P. (2016). Somatic TP53 Mutations in the Era of Genome Sequencing. Cold Spring Harbor Perspectives in Medicine. https://doi.org/10.1101/cshperspect.a026179
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
